David Southwell

Mr. David P.
Southwell is a Chief Executive Officer at Volastra Therapeutics, Inc., an Independent Director at Rocket Pharmaceuticals, Inc., an Independent Director at PTC Therapeutics, Inc. and an Independent Director at THL Credit Secured Floating Rate Debt Ltd. He is on the Board of Directors at Sensorium Therapeutics, Inc., Rocket Pharmaceuticals Ltd., Rocket Pharmaceuticals, Inc., PTC Therapeutics, Inc., Panel Intelligence LLC and THL Credit Secured Floating Rate Debt Ltd. Mr. Southwell was previously employed as a President, Chief Executive Officer & Director by TScan Therapeutics, Inc., a President, Chief Executive Officer & Director by Inotek Pharmaceuticals Corp., a Chief Financial Officer, Director & Executive VP by Human Genome Sciences, Inc., an Independent Director by First Eagle Alternative Capital BDC, Inc., a Chairman by BioSphere Medical, Inc., a Chief Financial Officer & Executive Vice President by Sunovion Pharmaceuticals, Inc., a Vice President-Investment Banking by Lehman Brothers, Inc., and a Chief Financial Officer by Bionevia Pharmaceuticals, Inc. He also served on the board at Spero Therapeutics, Inc., inVentiv Health, Inc. and MedPanel, Inc. He received his undergraduate degree from William Marsh Rice University and an MBA from Tuck School of Business at Dartmouth.